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Vascular Endothelial Growth Factor-d Modulates
Caliber and Function of Initial Lymphatics in the
Dermis
Sophie Paquet-Fifield1,2, Sidney M. Levy1,2,3,4, Teruhiko Sato2,6, Ramin Shayan1,2,3,4, Tara Karnezis1,2,
Natalia Davydova1,2, Cameron J. Nowell2, Sally Roufail1,2, Gerry Zhi-Ming Ma2, You-Fang Zhang1,2,
Steven A. Stacker1,2,4,5 and Marc G. Achen1,2,4,5
The lymphatic vasculature is important for skin biology as it maintains dermal fluid homeostasis. However, the
molecular determinants of the form and function of the lymphatic vasculature in skin are poorly understood.
Here, we explore the role of vascular endothelial growth factor-d (Vegf-d), a lymphangiogenic glycoprotein, in
determining the form and function of the dermal lymphatic network, using Vegf-d-deficient mice. Initial
lymphatic vessels in adult Vegf-d-deficient mice were significantly smaller than wild-type but collecting
lymphatics were unaltered. The uptake/transport of dextran in initial lymphatics of Vegf-d-deficient mice was
far less efficient, indicating compromised function of these vessels. The role of Vegf-d in modulating initial
lymphatics was further supported by delivery of Vegf-d in skin of wild-type mice, which promoted enlargement
of these vessels. Vegf-d-deficient mice were subjected to cutaneous wounding to challenge lymphatic function:
the resulting wound epithelium was highly edematous and thicker, reflecting inadequate lymphatic drainage.
Unexpectedly, myofibroblasts were more abundant in Vegf-d-deficient wounds leading to faster wound closure,
but resorption of granulation tissue was compromised suggesting poorer-quality healing. Our findings
demonstrate that Vegf-d deficiency alters the caliber of initial lymphatics in the dermis leading to reduced
functional capacity.
Journal of Investigative Dermatology (2013) 133, 2074–2084; doi:10.1038/jid.2013.83; published online 4 April 2013
INTRODUCTION
The lymphatic vasculature is important for tissue fluid home-
ostasis, immune function, and absorption of dietary fats, and
has a key role in a range of pathologies, including cancer,
chronic inflammation, and lymphedema (Baldwin et al., 2002;
Achen et al., 2005; Cueni and Detmar, 2008; Alitalo, 2011).
The growth of lymphatic vessels, lymphangiogenesis, is a
feature of wound healing (Paavonen et al., 2000; Maruyama
et al., 2007; Shayan et al., 2007) and facilitates the metastatic
spread of tumor cells (Mandriota et al., 2001; Skobe et al.,
2001; Stacker et al., 2001; Shayan et al., 2006; Achen and
Stacker, 2008; Tammela and Alitalo, 2010). In skin,
lymphangiogenesis can influence dermal fluid volume and
various forms of inflammation (Kajiya et al., 2009;
Huggenberger et al., 2010, 2011), although the molecular
determinants of the structure and function of the lymphatic
vasculature in skin are not well understood. The lymphatic
vasculature of the dermis primarily consists of initial
lymphatics, which absorb fluid from the interstitium, and
precollector vessels, which drain the lymph fluid into
subcutaneous collecting lymphatics (Oliver and Alitalo, 2005).
Lymphangiogenesis is in part controlled by members of the
vascular endothelial growth factor (Vegf) family of secreted
glycoproteins, in particular VEGF-C (Joukov et al., 1996) and
VEGF-D (Achen et al., 1998), signaling via the receptor
tyrosine kinase Vegf receptor (VEGFR)-3 (Makinen et al.,
2001; Veikkola et al., 2001; Haiko et al., 2008) located on
the surface of lymphatic endothelial cells (LECs) (Lymboussaki
et al., 1998). VEGF-D can stimulate pathologic lymphangio-
genesis, and induce dilation of collecting lymphatic vessels,
which facilitate lymph node and/or distant organ metastasis in
mouse models of cancer (Stacker et al., 2001; Von Marschall
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et al., 2005; Achen et al., 2006; Kopfstein et al., 2007;
Karnezis et al., 2012). Its expression in a range of human
cancers can correlate with metastasis and poor patient
outcome (Debinski et al., 2001; Stacker et al., 2004; Achen
et al., 2005). Human VEGF-D has been shown to promote
lymphangiogenesis and/or angiogenesis in healthy adult
tissues in a range of viral and protein delivery studies
(Marconcini et al., 1999; Byzova et al., 2002; Bhardwaj
et al., 2003; Rissanen et al., 2003; Wise et al., 2003;
Rutanen et al., 2004), is localized to vascular smooth
muscle cells associated with large arteries in human tissues
(Partanen et al., 2000; Achen et al., 2001; Rutanen et al.,
2003), and has been proposed to have a role in vascular
homeostasis (Achen et al., 2001; Rutanen et al., 2003).
The role of VEGF-D in the development of the lymphatic
vasculature in mammals is thought to be subtle (Koch et al.,
2009), with the only alteration reported to date in Vegf-d-
deficient mice under nonpathological conditions being a
reduction in the abundance of pulmonary lymphatics
(Baldwin et al., 2005). A study in Xenopus laevis tadpoles
showed that knockdown of VEGF-D transiently impaired LEC
migration and suggested a modifier role in the regulation of
embryonic lymphangiogenesis (Ny et al., 2008). These
findings are in contrast to Vegf-c, which has been shown to
have a key role in lymphatic development, being required for
sprouting of the first lymphatic vessels from embryonic veins
(Karkkainen et al., 2004).
Lymphangiogenesis occurs during cutaneous wound heal-
ing, and involves the sprouting of new VEGFR-3-positive
lymphatic vessels from pre-existing lymphatics at the wound
edge. These new lymphatics grow deep into the granulation
tissue, where they appear after the establishment of blood
vessels (Paavonen et al., 2000; Shimamura et al., 2009;
Martinez-Corral et al., 2012). The functional significance for
wound healing of these lymphatics, which later regress
(Paavonen et al., 2000), is unclear. In contrast, the
lymphatics in intact skin adjacent to cutaneous wounds are
known to have a role in draining some of the wound-derived
fluid (Shimamura et al., 2009).
Given that VEGF-D is a lymphangiogenic growth factor and
that the mouse vegfd gene is strongly expressed in developing
skin (Achen et al., 2001), Vegf-d could have a role in
development and function of the dermal lymphatic vascula-
ture. Here, we test the hypothesis that Vegf-d modulates the
structure and function of dermal lymphatics by monitoring the
morphology of the lymphatic network, and the function of the
lymphatics during cutaneous wound healing, in Vegf-d-
deficient mice. We report that Vegf-d deficiency modulates
the caliber and function of initial lymphatics in the dermis.
RESULTS
Initial lymphatics in the dermis are significantly smaller in
Vegf-d-deficient mice
We monitored dermal lymphatic vessels in adult male Vegf-d-
deficient mice (hemizygous vegfd /males; note the vegfd
gene is located on the X chromosome (Jenkins et al., 1997)) on
pure C57Bl/6 genetic background at three distinct anatomical
locations—tail, ear, and flank skin. Dermal lymphatic vessels,
predominantly initial lymphatics and precollectors, were
immunostained for the LEC marker LYVE-1 (Figure 1 and
Supplementary Materials and Methods online). Initial lympha-
tics in the dermis were significantly smaller in Vegf-d-deficient
mice than in wild-type littermate controls at all the anatomical
locations analyzed. The average size of these vessels in the
tails of Vegf-d-deficient mice (taking into account the endothe-
lium and the lumen as assessed in tissue sections) was 34%
smaller than in wild-type mice (Figure 1a and b), and,
similarly, the width of the initial lymphatics was 34% smaller
in the ears of Vegf-d-deficient mice, as assessed in tissue
whole mounts (Figure 1c and d). Further, there was a clear
alteration in the size distribution of initial lymphatics in the
flank dermis, with larger initial lymphatics (4480mm2 in size
as measured in tissue sections) being far more abundant in
wild-type than in Vegf-d-deficient mice (Figure 1e and f). We
found that there was no significant difference in the number of
endothelial cell nuclei per initial lymphatic vessel in the tails
of Vegf-d-deficient and wild-type mice (as detected by
immunohistochemistry on tissue sections) (Figure 1g), indicat-
ing that these vessels are smaller in Vegf-d-deficient mice
because the endothelial cells lining them are smaller, not
because there are fewer endothelial cells.
There was no difference in spatial distribution of initial
lymphatics in the dermis of the tail or flank (i.e., in the depth of
these vessels within the tissue) in Vegf-d-deficient compared
with wild-type mice (data not shown), nor in the density of
these lymphatic vessels (Figure 1h). The alteration in the size of
initial lymphatics in Vegf-d-deficient mice exhibited specificity
in terms of lymphatic subtypes given there was no difference
in the size, or location, of the major epifascial lymphatic
collecting vessels in the tails of these mice compared with
wild-type controls, as assessed by immunostaining for the LEC
marker podoplanin (Figure 1i and j). There were no significant
differences in overall density or size of blood vessels in the
dermis of the flank in Vegf-d-deficient compared with wild-
type mice, as assessed by staining for PECAM-1 (Figure 1k).
Initial lymphatics of Vegf-d-deficient mice are functionally
compromised
The functional capacity of initial lymphatics in the dermis to
absorb and transport macromolecules was assessed in the tail
by intravital lymphangiography. FITC–dextran was injected at
the tip of the tail, and its uptake and transport in the network
of initial lymphatics monitored over time by fluorescence
microscopy (see Figure 2a and b, and Materials and Methods).
The peak fluorescence intensity arising from the FITC–dextran
was similar in initial lymphatics of Vegf-d-deficient and wild-
type tails; however, the fluorescence intensity increased much
slower in Vegf-d-deficient lymphatics (Figure 2c and d). The
difference between the fluorescence intensity in the initial
lymphatics of Vegf-d-deficient mice compared with wild-type
was statistically significant over a prolonged period (i.e.,
B40 seconds) during the experiment. These findings indicate
that uptake and/or transport of dextran was far less efficient in
Vegf-d-deficient mice than in wild-type controls.
Perturbation in lymphatic function can lead to swelling
of tissue; however, there was no visual or histological evidence
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Figure 1. Initial lymphatics in the dermis are significantly smaller in adult vascular endothelial growth factor-d (Vegf-d)-deficient mice. (a) Initial lymphatics
(red) in dermis (white bar) are visualized by LYVE-1 staining in tail of wild-type (Wt) mouse, and (b) sizes of LYVE-1-positive vessels are compared in Wt and
Vegf-d-deficient (Ko) mice (n¼6). (c) Whole-mount LYVE-1 staining reveals abundant initial lymphatics (green) in the ear of Wt mouse, and (d) width of these
vessels is compared (n¼9 for Wt; 13 for Ko). (e) Initial lymphatics (arrowheads) in the dermis are detected in flank skin of Wt and Ko mice by LYVE-1 staining, and
(f) abundance of different size classes of these vessels is compared (n¼ 11 for Wt; 10 for Ko). (g) Abundance of 406-diamidino-2-phenylindole (DAPI)-stained
endothelial cell nuclei in initial lymphatics in tissue sections of dermis from Wt and Ko tails. (h) Density of initial lymphatics in the dermis of the tail and flank in
Wt and Ko mice. (i) An epifascial collecting lymphatic vessel (red) is visualized in the tail of Wt mouse by podoplanin staining, and (j) sizes of collecting lymphatics
are compared (n¼ 6 for Wt; 5 for Ko). (k) The density (left) and size (right) of PECAM-1-positive blood vessels in the dermis of flank skin are compared (n¼ 5 for
Wt; 6 for Ko). Graphs show mean±SEM, and statistical analysis was by Student t-test; *Po0.05; **Po0.01.
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of altered interstitial fluid volume in the skin of adult Vegf-d-
deficient mice. Hence, although the uptake and/or transport of
macromolecules in the initial lymphatics of these mice were
compromised, this was not sufficient to induce detectable
edema or lymphedema under nonpathological conditions.
Cutaneous wound healing in Vegf-d-deficient mice
The process of cutaneous wound healing involves accumula-
tion of fluid, which must ultimately be drained from the
wound region. It has been proposed that lymphatic vessels,
particularly in intact skin surrounding cutaneous wounds,
drain a proportion of the wound-derived fluid (Shimamura
et al., 2009). Therefore, we tested the functional capacity of
the dermal lymphatic network of Vegf-d-deficient mice by
generating full-thickness excisional wounds (6mm in
diameter) on the upper dorsal back. At day 7 post wounding
(pw), there was pronounced edema in the epithelium in Vegf-
d-deficient wounds, in contrast to wild-type (Figure 3a). The
fluid accumulation occurred between the keratinocytes in the
basal layer of the epithelium. The epithelium was also much
thicker, which was predominantly owing to the edema given
that there was no alteration in the number of cells across the
width of the epithelium (Figure 3b). The density of nuclei in
the basal layer of the wound epithelium was lower in Vegf-d-
deficient than in wild-type mice, consistent with the observed
edema (Figure 3b). The edema in the epithelium was no
longer apparent at day 10 pw, indicating it was restricted to
the early phase of the healing process. We did not detect
edema in the granulation tissue of Vegf-d-deficient wounds.
Interestingly, wounds closed faster in Vegf-d-deficient mice.
By day 6 pw, the fibrin clot had resolved whereas the wound
area of control mice was still covered by a large fibrin crust
until day 10 pw. Further, the rate at which the wound edges
approached each other between days 1 and 10 pw was
accelerated in Vegf-d-deficient mice (Figure 3c and d). We
observed that smooth muscle actin-positive myofibroblasts
were 4-fold more abundant at day 7 pw in the granulation
tissue of Vegf-d-deficient mice than in wild-type (Figure 3e),
but were of comparable abundance at day 10 pw. It is highly
likely that the faster rate of wound closure in Vegf-d-deficient
mice is owing to the increase in myofibroblasts, given that
these cells enhance the contraction of wounds (Grinnell, 1994).
We monitored the resorption of granulation tissue by staining
for collagen. Resorption begins at about day 10 pw in the
mouse, leads to thinner granulation tissue and is a hallmark of
wound maturation (James and Newcombe, 1961). As expected,
granulation tissue became significantly thinner from day 10 to
20 pw in wild-type wounds (Figure 3f); however, it did not alter
over this time period in Vegf-d-deficient wounds, suggesting
compromised wound remodeling.
We monitored lymphatic vessels in granulation tissue to
assess whether an altered lymphatic vasculature within
the wounds might have contributed to edema in the epithe-
lium (Figure 4a). There was no statistically significant
difference in the overall density of lymphatic vessels in the
granulation tissue of Vegf-d-deficient and wild-type mice
(Figure 4b, left graph). However, a higher proportion of these
lymphatics were small in Vegf-d-deficient granulation tissue
(see Figure 4b, right graph, for densities of various size classes
of lymphatics). Eighteen percentage of lymphatics in Vegf-d-
deficient granulation tissue were in the smallest size class (i.e.,
detected as being o78mm2 in tissue sections) as opposed to
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nine percentage for wild-type wounds. These findings indicate
subtly altered lymphangiogenesis and/or lymphatic modeling.
Levels of messenger RNA for Vegf-c (Figure 4e and
Supplementary Materials and Methods online) initially
increased during wound healing and returned to basal levels
by day 20 pw, and were comparable in Vegf-d-deficient and
wild-type wounds. In contrast, Vegf-d messenger RNA levels
decreased in wild-type mice throughout wound healing. We
also analyzed blood vessels in granulation tissue to assess
whether enhanced angiogenesis in Vegf-d-deficient wounds
might have contributed to faster wound closure. However,
there were no alterations in the size or density of blood
vessels in Vegf-d-deficient granulation tissue compared with
wild-type (Figure 4c and d), consistent with the finding
that levels of messenger RNA for the angiogenic protein
Vegf-a (Figure 4e) were not statistically different in Vegf-d-
deficient versus wild-type wounds at any of the time points
analyzed.
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Initial lymphatics in adult dermis enlarge in response to mouse
Vegf-d
The smaller caliber of initial lymphatics in the skin of Vegf-d-
deficient mice suggest that Vegf-d can promote enlargement of
initial lymphatic vessels. We tested the capacity of initial
lymphatics in the dermis of adult skin to respond to Vegf-d by
intradermally injecting 293EBNA-1 cells stably transfected
to express recombinant mature mouse Vegf-d (i.e., lacking
the N- and C-terminal propeptides in full-length Vegf-d
(Baldwin et al., 2001b)), or control cells harboring the
expression vector lacking Vegf-d sequence, into the ears of
SCID/NOD mice. 293EBNA-1 cells were used as a model
system because they do not produce significant quantities
of VEGF family members, and they form tumor xenografts
that do not induce significant lymphangiogenesis or
angiogenesis (Stacker et al., 2001)—hence they provide a
‘‘clean background’’ in which to assess the effects, through
transfection, of lymphangiogenic or angiogenic growth factors.
The mature form of Vegf-d was used instead of the full-length
form because it has been shown in studies of human VEGF-D
that proteolytic processing to remove the propeptides is
required to generate the most bioactive form of the protein
(Stacker et al., 1999; McColl et al., 2003, 2007; Harris et al.,
2011). Furthermore, the degree to which ectopically delivered
full-length mouse Vegf-d would have been proteolytically
activated in the dermis of the ear was unknown. Cells were
mixed with Matrigel before injection to ensure they would be
localized around the injection site, and ears were harvested 1
week after injection.
Staining of whole mounts with LYVE-1 revealed that
mouse Vegf-d promoted both the enlargement of initial
lymphatic vessels in the dermis (the width of these lymphatics
was about 70% larger) as well as sprouting to generate new
vessels, at a distance of 1mm from the Matrigel plug
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(Figure 5a and d). There was an abundance of sprouts
from almost all initial lymphatics in this region, but virtually
none in ears treated with control cells not expressing Vegf-d.
At B3mm from the plug, mouse Vegf-d promoted the
enlargement of initial lymphatics (the width of these
lymphatics was about 40% larger) but not vessel sprouting
(Figure 5b and d). Staining for PECAM-1 indicated that Vegf-d
increased the size, but not density, of blood vessels at a
distance of 1mm from the plug (Figure 5c and e), but neither
blood vessel size nor abundance was altered at a distance of
3mm (Figure 5e). The control cells, that did not express Vegf-
d, did not induce any significant effects on lymphatics or
blood vessels as assessed by comparison with injection of
Matrigel alone (data not shown). The findings at 3mm from
the plug, that mouse Vegf-d modulates the size, but not
abundance, of initial lymphatics in the dermis and does not
affect blood vessels, are consistent with the alterations
observed in Vegf-d-deficient skin.
DISCUSSION
The data presented here show that Vegf-d deficiency can lead
to significantly smaller initial lymphatic vessels in the dermis
of adult skin, an effect that was specific in terms of lymphatic
vessel subtypes given that collecting lymphatic vessels were
not altered in size or abundance. The reduced size of the
initial lymphatics in Vegf-d-deficient mice was owing to a
reduction in the size of the endothelial cells lining these
vessels—the molecular mechanisms by which Vegf-d signal-
ing modulates the size of LECs is yet to be fully determined.
The altered initial lymphatics in the dermis of Vegf-d-deficient
mice were less efficient in the uptake and/or transport of
dextran than in wild-type controls. This may be owing to the
reduced size of these lymphatics in Vegf-d-deficient mice;
however, other explanations, including effects on lymphatic
pump function, such as have been reported for VEGF-C
(Breslin et al., 2007), or on the ultrastructure of endothelial
cells lining initial lymphatic vessels, require exploration. The
dysfunction of these vessels was not sufficiently profound to
give rise to detectable edema or lymphedema under
nonpathological conditions. Vegf-d deficiency did not lead
to significant alteration in the size or abundance of blood
vessels in the dermis. Our finding that Vegf-d in wild-type
mice enlarges lymphatic vessels in skin is consistent with the
observation that tumor-derived VEGF-D promotes enlargement
of lymphatics in the setting of cancer (Karnezis et al., 2012).
The finding that the initial lymphatics in the dermis are
altered in adult Vegf-d-deficient mice but blood vessels are not
is consistent with transgenic mice in which full-length human
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Figure 5. Initial lymphatics in adult dermis are responsive to mouse vascular endothelial growth factor-d (Vegf-d). The ears of adult SCID/NOD mice were
intradermally injected with Matrigel containing 293-EBNA-1 cells stably transfected to express mature mouse Vegf-d (Vegf-d) or control cells transfected with
Apex expression vector lacking DNA sequence for Vegf-d (Control). After 1week, the ears were harvested, whole-mounted, and stained for LYVE-1 to visualize
initial lymphatics (green) in the dermis. Initial lymphatics were compared at distances of (a) 1mm or (b) 3mm from Matrigel plugs. An abundance of small
lymphatic sprouts is seen arising from many initial lymphatics in response to Vegf-d in a. (c) The region of the ear 1mm from the Matrigel plug was analyzed for
blood vessels (red) by PECAM-1 staining. (d) Width of initial lymphatics (n¼11) and (e) size (top) and density (bottom) of blood vessels (n¼5) are compared
(Cn denotes treatment with control cells; Vd denotes treatment with cells producing Vegf-d). Graphs show mean±SEM, and statistical analysis was by Student’s
t-test; *Po0.05; **Po0.01.
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VEGF-D (Veikkola et al., 2001) or mouse Vegf-d (Haiko et al.,
2008; Huggenberger et al., 2011) was expressed in epidermal
keratinocytes under the control of the cytokeratin 14 (K14)
promoter. These adult transgenic mice exhibited hyperplasia
of dermal lymphatic vessels but no alterations to blood
vessel architecture in the dermis. Our findings that initial
lymphatics and cutaneous wound healing are altered in
Vegf-d-deficient mice on pure C57Bl/6 genetic background
are in contrast to the previous work with Vegf-d-deficient
mice on mixed genetic backgrounds (Baldwin et al., 2005;
Koch et al., 2009) in which dermal lymphatics and wound
healing were normal. The different genetic backgrounds of
these Vegf-d-deficient mouse strains likely explain the
different phenotypes observed. There is precedence for the
genetic backgrounds of mice influencing the degree of
the lymphatic vascular phenotype resulting from the
targeting of a specific gene. For example, the phenotype of
mice in which the gene for the Sox18 transcription factor
had been inactivated varied markedly depending on the
genetic background, with an extremely strong phenotype
involving a complete blockade of LEC differentiation leading
to gross subcutaneous edema and fetal lethality for
homozygotes on pure C57BL/6 background (Francois et al.,
2008). In stark contrast, homozygotes on a mixed genetic
background were viable, fertile, and displayed only a mild
coat defect (Pennisi et al., 2000).
Mouse Vegf-d binds Vegfr-3 but has been reported to be a
poor ligand for Vegfr-2 (Baldwin et al., 2001a). Vegfr-3
signaling is known to be sufficient to drive the enlargement
of lymphatics in skin as illustrated by transgenic mice
expressing a Vegfr-3-specific mutant of VEGF-C (Veikkola
et al., 2001). Hence, the smaller initial lymphatics in the
dermis of Vegf-d-deficient mice likely arise owing to
inadequate Vegfr-3 signaling. In contrast, it is not clear why
expression of full-length mouse Vegf-d or human VEGF-D in
the skin of the K14 transgenic mice, or Vegf-d deficiency in
the mice studied here, did not alter the blood vessel size or
abundance in the dermis, given that delivery of mature or
full-length human VEGF-D in a range of tissues and tumor
models promoted angiogenesis (Marconcini et al., 1999;
Stacker et al., 2001; Byzova et al., 2002; Bhardwaj et al.,
2003; Rissanen et al., 2003; Rutanen et al., 2004). Possible
explanations include insufficient concentrations or proteolytic
processing of mouse Vegf-d (or human VEGF-D) in the skin
to drive angiogenesis or blood vessel enlargement, or
functional redundancy with other angiogenic growth factors,
such as Vegf-a.
The exact timing at which initial lymphatics in the dermis
of wild-type mice became larger than in Vegf-d-deficient
mice was difficult to pinpoint given that the difference in
vessel size in the adults was relatively subtle. An indication of
the time at which the dermal lymphatic vasculature becomes
sensitive to Vegf-d is provided by transgenic mice expressing
the K14-VEGF-D transgene. The hyperplasia in the dermal
lymphatics of these transgenic mice developed soon after birth
despite the transgene being expressed already by embryonic
day 14.5, suggesting that early postnatal lymphatic maturation
involves the acquisition of sensitivity to Vegf-d (Karpanen
et al., 2006b). The molecular mechanisms underlying this
observation are currently unknown, but could reflect the
timing or levels of expression of receptors for Vegf-d,
including Vegfr-3 (Achen et al., 1998), neuropilins
(Karpanen et al., 2006a; Harris et al., 2011), or integrin a9b1
(Vlahakis et al., 2005), on dermal LEC.
We assessed the capacity of initial lymphatics in the dermis
of adult SCID/NOD mice to respond to mature mouse Vegf-d,
which demonstrated that at high concentrations (i.e., proximal
to the source of protein) mouse Vegf-d promoted both the
enlargement of initial lymphatics as well as sprouting to form
new lymphatics, whereas at lower concentrations (i.e., more
distant from the source of Vegf-d) only lymphatic vessel
enlargement was observed. The result observed more distant
from the source of Vegf-d (i.e., that caliber of initial lympha-
tics, but not abundance, was altered) is consistent with our
observations in Vegf-d-deficient mice in that the absence of
Vegf-d led to reduced size, but not density, of initial
lymphatics in the dermis. Further, our study shows that initial
lymphatics in the adult are sensitive to mouse Vegf-d signal-
ing, as was shown to be the case during the postnatal period in
K14-VEGF-D transgenic mice expressing human VEGF-D
(Karpanen et al., 2006b), and has been reported for adult
skin in a rat study involving adenoviral delivery of human
VEGF-D (Byzova et al., 2002). We also observed enlargement
of blood vessels in response to mature mouse Vegf-d showing
that, although this protein has been reported to be a poor
ligand for Vegfr-2 (Baldwin et al., 2001a), it can elicit effects
on blood vessels, potentially via Vegfr-3 signaling (Tammela
et al., 2008, 2011; Benedito et al., 2012).
We monitored the effect of Vegf-d deficiency, and the
abnormality of initial lymphatics arising from it, in a full-
thickness cutaneous wound healing model designed to chal-
lenge lymphatic function. Wound healing in Vegf-d-deficient
mice was characterized by pronounced and acute edema in
the epithelium, which caused significant thickening of this
tissue layer. The epithelial edema likely resulted from com-
promised capacity of the initial lymphatics in normal
unwounded dermis immediately surrounding the wound to
absorb fluid (Shimamura et al., 2009). We also observed an
increase in the proportion of lymphatics that were small in the
granulation tissue of Vegf-d-deficient wounds, although there
was no difference in the overall density of lymphatics in this
tissue, which is consistent with our observation that Vegf-d
promotes the enlargement of these vessels. The altered
lymphatics in the granulation tissue may also have
contributed to the edema in the epithelium. These findings
indicate that although Vegf-d deficiency (and the resulting
lymphatic dysfunction in fluid uptake/transport) did not lead to
dermal edema in nonpathological conditions, it was sufficient
to do so during cutaneous wound healing.
Unexpectedly, myofibroblasts were far more abundant in
the granulation tissue of Vegf-d-deficient wounds, which likely
explained the faster wound closure from days 1 to 10 pw,
given that these cells enhance contractility of wound beds
(Grinnell, 1994). Although the molecular mechanisms leading
to more abundant myofibroblasts in Vegf-d-deficient wounds
are unknown, it is recognized in a clinical setting that lymph
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stasis can lead to more fibroblasts in skin (Tabibiazar et al.,
2006). Hence, it is conceivable that the edema in Vegf-d-
deficient wounds promoted myofibroblast recruitment. We
also observed altered remodeling of granulation tissue in Vegf-
d-deficient wounds suggesting a compromised quality of
healing. The altered remodeling was not owing to a
difference in the abundance of macrophages given that F4/
80-positive macrophages were equally abundant in the
granulation tissue of Vegf-d-deficient and wild-type wounds
at day 10 pw (data not shown). It is not known whether the
effects of Vegf-d-deficiency on fibroblast abundance or
remodeling of the granulation tissue are a consequence of
altered lymphatic vessel function or owing to direct effects of
Vegf-d on other components of healing wounds. These aspects
require further investigation involving systems biology
approaches to broadly monitor the effects of Vegf-d on the
variety of cell types involved in wound healing. Our
observations in cutaneous wound healing suggest that Vegf-
d deficiency leads to faster wound closure but a compromised
quality of healing. Given the poorer quality of healing, this
scenario is likely to be detrimental, but further work is
required to assess the significance of Vegf-d-deficiency for
different types of wounds.
In conclusion, our study is the first to show that Vegf-d is a
determinant of the caliber of initial lymphatic vessels in the
dermis and the capacity of these vessels to absorb and/or
transport macromolecules. Although not required for the
formation of the lymphatic vasculature, Vegf-d is important
for ‘‘fine-tuning’’ the structure and function of initial lymphatic
vessels in the dermis.
MATERIALS AND METHODS
Mice
Mice with targeted inactivation of the vegfd gene, on a mixed
C57Bl/6 and 129SV genetic background (Baldwin et al., 2005),
were backcrossed to C57Bl/6 mice for 10 generations and used for
this study. SCID/NOD mice were from the Australian Resource
Centre. Experiments were conducted according to ethical guidelines
of the National Health and Medical Research Council of Australia.
Lymphangiography
Hair was removed from the tails of anesthetized mice with depilatory
cream, and mice placed in a chamber at 37 1C in an IX81 Olympus
microscope (Mt Waverley, Victoria, Australia) connected to a Lambda
XL Xenon plasma lamp (Sutter Instruments, Novato, CA). Tails were
immobilized with tape and tail tips injected intradermally with 20ml
of 25mgml 1 FITC–Dextran (2000KD, Sigma) using a 29 gauge
syringe. The fluorescent signal within initial lymphatics located
2.5 cm from the tail tip was recorded every second for 50minutes.
Images were captured using an  4 objective and data analysis was
with MetaMorph software (Version 7.6.2, Molecular Devices, Middle
Cove, New South Wales, Australia).
Wound healing
Eight to 10-week-old hemizygous vegfdo/ and wild-type male mice
were anesthetized by intraperitoneal injection of xylazine (20mgkg 1)
and ketamine (100mgkg 1). They were shaved on the back and
treated with depilatory cream (Veet, Reckitt Benckiser, Slough, UK)
for 1minute, followed by rinsing with warm water, then 70% ethanol.
Two 6-mm-diameter full-thickness excisional wounds were made on
the upper dorsal back, one on each side of the spine, using a biopsy
punch (Kai Industries, Gifu, Japan)—the skin collected through the
punch biopsies was used as a control (Day 0). All wounds analyzed
were free of infection and contamination with hair. Four mice were
used per time point, and each time point was performed in duplicate.
Wounds were not dressed and mice were housed individually until
harvesting. Wounds were measured with callipers and photographed
with an Olympus SP-550UZ digital camera. At selected time points,
mice were killed and wound biopsies, surrounded by a 5-mm margin
of tissue, were harvested with scissors. The orientation of samples for
embedding was always the same. Skin samples were fixed flat in
porous holders in 4% paraformaldehyde, cut in half by transverse
incision, and embedded in paraffin. Samples were sectioned vertically
over the middle of the wound.
Injection of matrigel plugs into the ear for delivery of Vegf-d
293EBNA-1 cells stably transfected to express a mature form of mouse
Vegf-d (Achen et al., 2000; Baldwin et al., 2001a) or control cells
stably transfected with expression vector lacking DNA sequence for
Vegf-d were grown in Dulbecco’s Modified Eagle Medium containing
10% fetal calf serum. Secretion of Vegf-d was verified by western
blotting as described previously (Harris et al., 2011). Cells (2.5 105)
were resuspended in 30ml of Matrigel (Matrigel Basement Membrane
Matrix, BD Biosciences) and injected into the center of an ear of an
8-week old SCID/NOD mouse. Ears were harvested for processing
one week later.
Computer-assisted morphometric vessel analysis
For flank wounds, images were taken on a Nikon Eclipse 90i
microscope with a x20/NA 0.6 PlanApo objective and a digital
camera (Coolsnap HQ, Photometrics). Four individual fields
per section in non-wounded samples and three in wounded samples
(one in the wound bed and one at each wound edge) were randomly
photographed—fewer images were taken for wounded samples
because they were smaller than non-wounded samples. Morpho-
metric analysis was performed using MetaMorph Premier (Version
7.6.2) software program (Molecular Devices). Each vessel was out-
lined to quantify its size (assessed as number of pixels in endothelium
and lumen) and the number of vessels per image. For the analysis of
lymphatics in whole mounts, the ‘‘Lymphatic Vessel Analysis Proto-
col’’ plug-in was used as described (Shayan et al., 2007).
Statistical analysis
Results were evaluated using Excel 2003 (Microsoft, Los Angeles, CA)
or Graph Pad Prism 4.0 (GraphPad Software, San Diego, CA)
software. Data are shown as mean±SEM as indicated, and were
analyzed with a two-tailed unpaired Student’s t-test. For all analyses,
Po0.05 was considered significant.
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